Updating results

1422 results

Sort: Relevance | Date

Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 07 April 2021

NICE guideline In development

Epilepsies in children, young people and adults

In development [GID-NG10112] Expected publication date: 02 June 2021

NICE guideline In development

Atrial fibrillation: management

In development [GID-NG10100] Expected publication date: 17 September 2020

NICE guideline In development

Joint replacement (primary): hip, knee and shoulder

In development [GID-NG10084] Expected publication date: 25 March 2020

NICE guideline In development

Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10143] Expected publication date: 12 February 2020

NICE guideline In development

Depression in adults: treatment and management

In development [GID-CGWAVE0725] Expected publication date: TBC

NICE guideline In development

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2019)

In development [GID-NG10087] Expected publication date: 30 March 2020

NICE guideline In development

Caesarean section (Update)

In development [GID-NG10081] Expected publication date: 21 January 2021

NICE guideline In development

Colorectal cancer: diagnosis and management (update)

In development [GID-NG10060] Expected publication date: 29 January 2020

NICE guideline In development

Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: 05 November 2020

NICE guideline In development

Skin tumours including Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 04 April 2022

NICE guideline In development

Rehabilitation in adults with complex psychosis and related severe mental health conditions

In development [GID-NG10092] Expected publication date: 19 June 2020

NICE guideline In development

Neonatal parenteral nutrition

In development [GID-NG10037] Expected publication date: 26 February 2020

NICE guideline In development

Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 20 May 2021

NICE guideline In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 04 April 2022

NICE guideline In development

Antenatal care for uncomplicated pregnancies update

In development [GID-NG10096] Expected publication date: 21 April 2021

NICE guideline In development

Tinnitus: assessment and management

In development [GID-NG10077] Expected publication date: 11 March 2020

NICE guideline In development

Diabetes in pregnancy: management from preconception to the postnatal period

In development [GID-NG10158] Expected publication date: TBC

NICE guideline In development

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

In development [GID-NG10161] Expected publication date: TBC

NICE guideline In development

Type 1 diabetes in adults: diagnosis and management (update)

In development [GID-NG10159] Expected publication date: TBC

NICE guideline In development

Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

NICE guideline In development

Acute kidney injury: prevention, detection and management (update)

In development [GID-NG10117] Expected publication date: 18 December 2019

NICE guideline In development

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

NICE guideline In development

Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 26 August 2021

NICE guideline In development

Rehabilitation after Traumatic injury

In development [GID-NG10105] Expected publication date: 04 August 2021

NICE guideline In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development

Acute coronary syndromes

In development [GID-NG10085] Expected publication date: 30 July 2020

NICE guideline In development

Multiple sclerosis in adults: management

In development [GID-NG10153] Expected publication date: 04 May 2022

NICE guideline In development

Self harm in over 8s: management and preventing recurrence

In development [GID-NG10148] Expected publication date: 26 January 2022

NICE guideline In development

Management of gout

In development [GID-NG10151] Expected publication date: 04 April 2022

NICE guideline In development

Neonatal infection (early onset): antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 05 March 2021

NICE guideline In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Lenalidomide for previously treated follicular lymphoma and marginal zone lymphoma [ID1374]

In development [GID-TA10323] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)

NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence

Technology appraisal guidance Published December 2018

Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)

NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published December 2018

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Technology appraisal guidance Published September 2019

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Technology appraisal guidance Published September 2019

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Technology appraisal guidance Published September 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Technology appraisal guidance Published May 2019

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)

NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was

Technology appraisal guidance Published March 2017

Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)

NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was

Technology appraisal guidance Published March 2017

Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in

Technology appraisal guidance Published October 2002

Guidance on the use of ultrasound locating devices for placing central venous catheters (TA49)

Evidence-based recommendations on ultrasound locating devices for placing central venous catheters into the internal jugular vein

Technology appraisal guidance Published October 2002

Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary

Technology appraisal guidance Published September 2002 Last updated March 2010

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Technology appraisal guidance Published March 2019

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Technology appraisal guidance Published February 2019